Marker Therapeutics (MRKR) Price/OCF Ratio: History & Chart

Marker Therapeutics, Inc.(MRKR)

Biotechnology · Houston, TX

$1.02-0.04 (-3.77%)

Delayed quote: Oct 6, 2026, 10:44 AM EDT

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A cornerstone of their approach is the proprietary MultiTAA-specific T cell technology. This method involves producing T cells that are not genetically modified but are specifically designed to target tumors. These specialized T cells can identify multiple antigens associated with tumors, allowing them to effectively eliminate cancer cells that express these markers. Marker Therapeutics' MultiTAA-specific T cell therapies encompass patient-derived (autologous) T cells for treating lymphoma and various solid tumors, as well as donor-derived (allogeneic) T cells for acute myeloid leukemia and acute lymphoblastic leukemia. They also provide "off-the-shelf" solutions applicable to a range of diseases. In addition to T cell therapies, the company is advancing peptide-based immunotherapeutic vaccines. This pipeline includes TPIV100/110, developed to combat breast and ovarian cancer cells, and TPIV200, which is currently undergoing Phase 2 clinical trials for the treatment of breast and ovarian cancers. Founded in 1999, Marker Therapeutics maintains its headquarters in Houston, Texas.

Houston, TX

5 employees

www.markertherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Juan F. Vera

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Marker Therapeutics, Inc. (MRKR)	$17.01M	N/A	N/A	N/A	N/A
Lipocine Inc. (LPCN)vs ›	$17.08M	N/A	N/A	N/A	N/A
Bionano Genomics, Inc. (BNGO)vs ›	$16.81M	N/A	N/A	N/A	N/A
Dyadic International, Inc. (DYAI)vs ›	$16.58M	N/A	43.53	44.24	48.21
BioCardia, Inc. (BCDA)vs ›	$15.93M	N/A	64.40	51.01	44.81
Allarity Therapeutics, Inc. (ALLR)vs ›	$15.75M	N/A	N/A	N/A	N/A
Cocrystal Pharma, Inc. (COCP)vs ›	$15.58M	N/A	57.00	57.00	57.00
Cosmos Health Inc. (COSM)vs ›	$18.38M	N/A	14.35	40.20	40.20
Estrella Immunopharma, Inc. (ESLA)vs ›	$18.61M	N/A	N/A	N/A	N/A
NextCure, Inc. (NXTC)vs ›	$18.71M	N/A	3510.40	3510.40	3510.40

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Marker Therapeutics, Inc. (MRKR)

$17.01M

N/A

Lipocine Inc. (LPCN)vs ›

$17.08M

N/A

Bionano Genomics, Inc. (BNGO)vs ›

$16.81M

N/A

Dyadic International, Inc. (DYAI)vs ›

$16.58M

N/A

43.53

44.24

48.21

BioCardia, Inc. (BCDA)vs ›

$15.93M

N/A

64.40

51.01

44.81

Allarity Therapeutics, Inc. (ALLR)vs ›

$15.75M

N/A

Cocrystal Pharma, Inc. (COCP)vs ›

$15.58M

N/A

57.00

Cosmos Health Inc. (COSM)vs ›

$18.38M

N/A

14.35

40.20

Estrella Immunopharma, Inc. (ESLA)vs ›

$18.61M

N/A

NextCure, Inc. (NXTC)vs ›

$18.71M

N/A

3510.40

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

MRKR Price/OCF Ratio Metrics

MRKR Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics